At Ichnos Glenmark Innovation, there are three engines of innovation. Company headquarters in the United States in New York City, a biologics research center in Lausanne, Switzerland, and a small molecule research center in Navi Mumbai, Maharashtra, India.

As the heart of our biologics innovation, our Research Center in Lausanne focuses on the discovery and development of biologics and is home to Ichnos Glenmark Innovation’s groundbreaking BEAT^® platform. IGI’s Biologics Research Center is comprised of protein engineers and in-vitro/in-vivo pharmacologists.

Our Small Molecule Research Center is housed in a 127,000+ sq. ft. campus at Mahape on the outskirts of Mumbai, India. It has end-to-end capabilities for discovery and development of small molecules from target selection to clinical development. The research facility is equipped with modern infrastructure required to carry out research activities like process and analytical chemistry, discovery, in-vitro and in-vivo pharmacology, tissue culture, toxicology and pharmacokinetics.

Serving as the base of operations for the organization, the corporate headquarters for Ichnos Glenmark Innovation, located in New York City, includes the clinical development teams and support functions.